List of Soolantra drug patents

Soolantra is owned by Galderma Labs Lp.

Soolantra contains Ivermectin.

Soolantra has a total of 12 drug patents out of which 0 drug patents have expired.

Soolantra was authorised for market use on 19 December, 2014.

Soolantra is available in cream;topical dosage forms.

Soolantra can be used as treatment of inflammatory lesions of rosacea..

The generics of Soolantra are possible to be released after 13 March, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033565 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(1 year, 2 months from now)

US8470788 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(1 year, 2 months from now)

US7550440 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(1 year, 2 months from now)

US8815816 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(1 year, 2 months from now)

US8093219 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(1 year, 2 months from now)

US8080530 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(1 year, 2 months from now)

US8415311 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(1 year, 2 months from now)

US9089587 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(11 years from now)

US9233117 GALDERMA LABS LP Treatment of inflammatory lesions of rosacea with ivermectin
Mar, 2034

(11 years from now)

US9782425 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(11 years from now)

US10206939 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(11 years from now)

US9233118 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(11 years from now)

Drugs and Companies using IVERMECTIN ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

How can I launch a generic of SOOLANTRA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in